Immunohistochemical staining of human breast cancer tissue array samples showed that ERLIN2 is highly expressed in aggressive breast cancer tumors, including invasive breast carcinoma, intraductal carcinoma, mucinous carcinoma, lipid secreting carcinoma and papillary carcinoma (Figure 1f). Here, ERLIN2 is linked to thyroid gland papillary carcinoma.